GLP-1, GIP, and Glucagon: Receptor Biology and Research Applications

The current generation of metabolic research peptides converges on three receptors. Understanding their biology — where each is expressed, what signalling cascades they trigger, and how they interact — is essential context for any research programme involving Semaglutide, Tirzepatide, or Retatrutide.

The GLP-1 receptor

The GLP-1 receptor (GLP-1R) is a class B G-protein coupled receptor expressed primarily on pancreatic beta cells, hypothalamic neurons, gastric epithelium, and cardiomyocytes. Activation triggers Gαs-mediated cAMP accumulation, which in beta cells potentiates glucose-dependent insulin secretion. In the central nervous system, GLP-1R activation in arcuate nucleus neurons reduces appetite. Peripherally, it slows gastric emptying.

The GIP receptor

The GIP receptor (GIPR) is also a class B GPCR, expressed on beta cells, adipocytes, and bone osteoblasts. Like GLP-1R, it couples to Gαs and elevates cAMP, but its effects on adipose tissue lipid metabolism are distinct: GIP enhances triglyceride storage under conditions of nutrient excess. The interplay between this adipose action and the systemic effects of dual agonism remains an active research area.

Tirzepatide demonstrates greater potency at the GIP receptor than native GIP itself, a feature engineered through specific amino acid substitutions in the GIP backbone.

The glucagon receptor

Historically framed as the counter-regulatory partner to insulin, the glucagon receptor (GCGR) is expressed primarily on hepatocytes but also on adipocytes and cardiomyocytes. Activation drives hepatic glycogenolysis and gluconeogenesis — which is why glucagon agonism alone would be hyperglycaemic. In a multi-receptor agonist context, however, the GLP-1 and GIP-driven insulin secretion offsets the hyperglycaemic effect, leaving the beneficial outcomes: thermogenesis, lipolysis, hepatic fatty acid oxidation, and PCSK9 degradation.

Cross-talk and convergence

All three receptors signal predominantly through Gαs-cAMP-PKA, but downstream substrate phosphorylation and tissue-specific cofactor expression produce divergent functional outcomes. Receptor heterodimerisation (particularly GLP-1R / GIPR) has been observed in some experimental systems and may contribute to the synergy observed with dual agonist compounds.

Research applications

For receptor binding affinity studies, structure-activity relationship work, and downstream signalling investigations, having access to high-purity comparator compounds for all three receptor profiles (Semaglutide for single, Tirzepatide for dual, Retatrutide for triple) enables rigorous comparative work. All three are available in our research catalogue with independent HPLC and mass spectrometry verification.